An unbranded injection pen on a linen cloth next to a glass of water

Oct 1, 2026

GLP-1 Pills in 2026: Oral Wegovy vs Foundayo, Compared

As of October 2026, people who want a GLP-1 medicine for weight management without a weekly injection have two FDA-approved pills to discuss with a provider: oral Wegovy (semaglutide, approved December 22, 2025) and Foundayo (orforglipron, approved April 2026). Both start at $149 a month cash at the lowest dose through the manufacturers’ own pharmacies. And on September 30, 2026, new real-world data presented at EASD in Milan showed that people who switched from a GLP-1 injection to the semaglutide pill kept losing weight. Here is how the two pills compare, with the trade-offs included.

Key facts

Oral Wegovy (semaglutide 25 mg, once daily) was FDA-approved on Dec 22, 2025. In the 64-week OASIS 4 trial, average weight loss was 13.6% vs 2.2% on placebo.
Foundayo (orforglipron, once daily) was FDA-approved in April 2026. In the 72-week ATTAIN-1 trial of 3,127 adults, the top dose averaged 11.2% weight loss vs 2.1% on placebo.
Foundayo can be taken any time of day, without food or water rules. The semaglutide pill is taken on an empty stomach with no more than 4 oz of water, then a 30-minute wait.
Cash prices (as of Oct 2026): Wegovy pill $149 to $299 a month by dose on NovoCare; Foundayo from $149 a month on LillyDirect.
On Sept 30, 2026, a study of 194 people who switched from an injection to the semaglutide pill reported 4.1% average additional weight loss (8.8 lbs) after 3 months.

Is there a GLP-1 pill for weight loss?

Yes, two. For years, the only FDA-approved GLP-1 medicines for chronic weight management were injections such as Wegovy and Zepbound. That changed when the FDA approved the once-daily semaglutide tablet for weight management in December 2025, followed by Lilly’s orforglipron, sold as Foundayo, in April 2026.

Both are prescription medicines approved for adults with obesity, or overweight with a weight-related health problem, used alongside diet and physical activity. Neither is a supplement, and neither is sold over the counter.

Oral Wegovy vs Foundayo: how the results compare

The two pills were tested in different trials, with different people and different lengths, so their numbers are not a head-to-head comparison. With that caveat:

Oral Wegovy (OASIS 4): 307 adults without diabetes, 64 weeks. Average weight loss was 13.6% on semaglutide vs 2.2% on placebo. In an estimate that assumes everyone kept taking the pill as directed, the figure was 16.6%.
Foundayo (ATTAIN-1): 3,127 adults without diabetes, 72 weeks, published in the New England Journal of Medicine. Average weight change was -7.5%, -8.4% and -11.2% on the three doses tested, vs -2.1% on placebo. Among people who stayed on treatment, the top dose reached 12.4% (about 27.3 lbs).

For context, injectable semaglutide and tirzepatide have posted larger average losses in their own trials. Our semaglutide vs tirzepatide comparison covers those numbers.

The daily routine: the biggest practical difference

This is where the pills really differ, according to a JAMA summary of the Foundayo approval:

Semaglutide pill: first thing in the morning on an empty stomach, with no more than 4 oz of water, then a wait of at least 30 minutes before eating, drinking or taking other medicines.
Foundayo: any time of day, with or without food or water.

For people with complex morning medication schedules, that flexibility is something worth raising with a provider.

Side effects, told plainly

Both pills work on the same GLP-1 receptor as the injections, and the side effect pattern is similar:

In OASIS 4, gastrointestinal side effects (such as nausea) affected 74.0% of people on the semaglutide pill vs 42.2% on placebo. They were mostly mild or moderate.
In ATTAIN-1, side effects led 5.3% to 10.3% of people on orforglipron to stop treatment, vs 2.7% on placebo. The most common were gastrointestinal and typically mild to moderate.

Neither pill is right for everyone. A licensed provider reviews medical history, other medicines and goals before prescribing either one.

New this week: switching from an injection to the pill

At the EASD annual meeting in Milan on September 30, 2026, Novo Nordisk presented the Octane study, a retrospective look at adults on the Ro telehealth platform who switched from injectable semaglutide or tirzepatide to the semaglutide pill between January 5 and February 7, 2026. Among the 194 people in the final sample, average weight loss was 4.1% (8.8 lbs) after three months on the pill, and participants reported satisfaction with the switch.

The honest limits: it followed people for only three months, it looked back at records rather than randomizing anyone, the sample was small, and it was sponsored by the pill’s maker. It suggests switching can work for some people. It does not prove the pill matches the injection long term.

Is a GLP-1 pill a peptide?

Here is a fun distinction. Semaglutide is a peptide, whether injected or swallowed (see why GLP-1s are peptides). Orforglipron is not. It is a small-molecule drug that acts on the same GLP-1 receptor without a peptide structure, which is part of why it can be taken without the strict empty-stomach routine.

What it costs (as of Oct 2026)

Wegovy pill on NovoCare Pharmacy: $149 a month (1.5 mg), $199 (4 mg), and $299 (9 mg and 25 mg).
Foundayo on LillyDirect: $149 a month (0.8 and 2.5 mg), $199 (5.5 mg) and $299 (9 mg and up) when each refill is filled within 45 days; the two highest doses rise to $349 otherwise. People with commercial insurance and a savings card may pay as little as $25 a month.

Prices change often. Our GLP-1 price tracker and guide to GLP-1 telehealth costs keep the bigger picture.

What it means for you

The arrival of two approved GLP-1 pills is good news for access: more choice, lower entry prices and an option for people who would rather avoid needles. Which one fits, or whether an injection fits better, depends on health history, other medicines, daily routine and budget. That is a conversation for a licensed provider, who can prescribe an FDA-approved product through a legitimate pharmacy. Both pills are FDA-approved medicines, so their status is clear; for peptides with less settled status, see our legal status tracker.

Sources

Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.

← All articles